Skip to main content
. 2021 Nov 22;12:6777. doi: 10.1038/s41467-021-26926-0

Fig. 6. mRNA adduction reduces protein expression.

Fig. 6

a Isolated main peak (MP) and late eluting-peak (LP) alongside control mRNA-lipid nanoparticle (mRNA-LNP) and an assay positive control were tested for in vitro protein expression in BJ fibroblasts after 48 h. RNA was extracted from 2 hEPO-LNP formulations by isopropanol precipitation and purified by RP-IP to generate MP and LP prior to transfection. The assay control is a pure hEPO mRNA standard, the control sample is mRNA extracted from each formulation prior to RP-IP separation, and the MP and LP are isolated fractions. Results from 2 replicate transfection wells is plotted with the mean. b Five different mRNA-LNP samples were prepared using different ionizable lipids and incubated at 5 °C to generate varying levels of adduct and degradation. RNA was extracted from the mRNA-LNP by isopropanol precipitation and evaluated by reversed phase-ion pair (RP-IP), capillary electrophoresis (CE), and in vitro protein expression in HeLa cells as measured by mean fluorescence intensity. Relative expression as a percentage of the neat mRNA expression is plotted versus relative integrity as a percentage of the neat mRNA integrity, determined by relative area using both CE and RP-IP HPLC. c Loss in mRNA purity to adduct formation in 2 vaccine formulations is plotted over 3 months at refrigerated conditions. Poor process control led to high LP in Vaccine A, but adduct was well-controlled in Vaccine B. Representative data are shown for 3 repeat experiments for Fig. 6a and multiple repeat experiments for Fig. 6b and c.